Generics drive Amerisource financials; Facilities planned, completed and approved;
> Big 3 drug distributor Amerisource cites sales of generics as a driver in its higher-than-expected quarterly profit growth. Article
> The FDA has approved Orthovita's facility in Malvern, PA, for collagen processing and the manufacture of collagen-based products. Article
> Novavax has been issued U.S. Patent No. 7,763,450, "Functional Influenza Virus-Like Particles (VLPS)," for the manufacturing process that uses influenza gene sequences for production of vaccines to protect against current and future seasonal and pandemic flu strains. Release
> Meridian Life Science is boosting investment in facilities, equipment and infrastructure to provide R&D support for contract manufacturing and custom biologics development. Release
> ATMI has completed the expansion of its Bloomington, MN, manufacturing facility, the North American hub for production and development of the Integrity single-use technology products. Announcement
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities

SHARE
WITH: